Terms: = Prostate cancer AND CCND3, P30281, 896, ENSG00000112576 AND Diagnosis
13 results:
1. Highly accurate and effective deep neural networks in pathological diagnosis of prostate cancer.
Zhang C; Gao X; Fan B; Guo S; Lyu X; Shi J; Fu Y; Zhang Q; Liu P; Guo H
World J Urol; 2024 Feb; 42(1):93. PubMed ID: 38386116
[TBL] [Abstract] [Full Text] [Related]
2. Non-Invasive diagnosis of prostate cancer and High-Grade prostate cancer Using Multiparametric Ultrasonography and Serological Examination.
Li J; Zhu C; Yang S; Mao Z; Lin S; Huang H; Xu S
Ultrasound Med Biol; 2024 Apr; 50(4):600-609. PubMed ID: 38238199
[TBL] [Abstract] [Full Text] [Related]
3. Meta-analysis of
Yu W; Zhao M; Deng Y; Liu S; Du G; Yan B; Zhao Z; Sun N; Guo J
Cancer Imaging; 2023 Aug; 23(1):77. PubMed ID: 37605288
[TBL] [Abstract] [Full Text] [Related]
4. Diagnostic Performance and Safety of Positron Emission Tomography with
Surasi DS; Eiber M; Maurer T; Preston MA; Helfand BT; Josephson D; Tewari AK; Somford DM; Rais-Bahrami S; Koontz BF; Bostrom PJ; Chau A; Davis P; Schuster DM; Chapin BF;
Eur Urol; 2023 Oct; 84(4):361-370. PubMed ID: 37414702
[TBL] [Abstract] [Full Text] [Related]
5. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract] [Full Text] [Related]
6. prostate cancer incidence and survival in relation to prostate cancer as second cancer in relatives.
Zheng G; Sundquist J; Sundquist K; Ji J
Cancer Med; 2022 May; 11(10):2117-2124. PubMed ID: 35312170
[TBL] [Abstract] [Full Text] [Related]
7. Medical image segmentation and reconstruction of prostate tumor based on 3D AlexNet.
Chen J; Wan Z; Zhang J; Li W; Chen Y; Li Y; Duan Y
Comput Methods Programs Biomed; 2021 Mar; 200():105878. PubMed ID: 33308904
[TBL] [Abstract] [Full Text] [Related]
8. Illuminating Clues of cancer Buried in prostate MR Image: Deep Learning and Expert Approaches.
Akatsuka J; Yamamoto Y; Sekine T; Numata Y; Morikawa H; Tsutsumi K; Yanagi M; Endo Y; Takeda H; Hayashi T; Ueki M; Tamiya G; Maeda I; Fukumoto M; Shimizu A; Tsuzuki T; Kimura G; Kondo Y
Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31671711
[TBL] [Abstract] [Full Text] [Related]
9. prostate cancer diagnosis on Repeat Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling.
Chelluri R; Kilchevsky A; George AK; Sidana A; Frye TP; Su D; Fascelli M; Ho R; Abboud SF; Turkbey B; Merino MJ; Choyke PL; Wood BJ; Pinto PA
J Urol; 2016 Jul; 196(1):62-7. PubMed ID: 26880408
[TBL] [Abstract] [Full Text] [Related]
10. Expression of livin, survivin and caspase-3 in prostatic cancer and their clinical significance.
Gu J; Ren L; Wang X; Qu C; Zhang Y
Int J Clin Exp Pathol; 2015; 8(11):14034-9. PubMed ID: 26823716
[TBL] [Abstract] [Full Text] [Related]
11. Choline intake and risk of lethal prostate cancer: incidence and survival.
Richman EL; Kenfield SA; Stampfer MJ; Giovannucci EL; Zeisel SH; Willett WC; Chan JM
Am J Clin Nutr; 2012 Oct; 96(4):855-63. PubMed ID: 22952174
[TBL] [Abstract] [Full Text] [Related]
12. Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk.
Cooper ML; Adami HO; Grönberg H; Wiklund F; Green FR; Rayman MP
Cancer Res; 2008 Dec; 68(24):10171-7. PubMed ID: 19074884
[TBL] [Abstract] [Full Text] [Related]
13. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
[TBL] [Abstract] [Full Text] [Related]
